JPS6452792A - Production of blood platelet growth factor - Google Patents

Production of blood platelet growth factor

Info

Publication number
JPS6452792A
JPS6452792A JP62209946A JP20994687A JPS6452792A JP S6452792 A JPS6452792 A JP S6452792A JP 62209946 A JP62209946 A JP 62209946A JP 20994687 A JP20994687 A JP 20994687A JP S6452792 A JPS6452792 A JP S6452792A
Authority
JP
Japan
Prior art keywords
human urine
molecular sieves
production
growth factor
blood platelet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP62209946A
Other languages
Japanese (ja)
Inventor
Yoji Ishida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyobo Co Ltd
Original Assignee
Toyobo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyobo Co Ltd filed Critical Toyobo Co Ltd
Priority to JP62209946A priority Critical patent/JPS6452792A/en
Publication of JPS6452792A publication Critical patent/JPS6452792A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

PURPOSE:To obtain the titled factor useful for hematopiesis after chemotherapy, radiotherapy or transplanting of bone marrow for cancer, by keeping human urine under alkaline condition and treating the human urine with molecular sieves. CONSTITUTION:Human urine is kept under alkaline condition and then treated with molecular sieves to afford the aimed factor. Furthermore, human urine collected from a patient suffering from a plastic anemia is preferably used as the human urine and pH is preferably kept at >=7.5. Membranes or gels of molecular sieves having about 50,000-200,000 cut molecular weight or gels (e.g. dextran or polyacrylamide derivative) are preferably used as the molecular sieves.
JP62209946A 1987-08-24 1987-08-24 Production of blood platelet growth factor Pending JPS6452792A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP62209946A JPS6452792A (en) 1987-08-24 1987-08-24 Production of blood platelet growth factor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP62209946A JPS6452792A (en) 1987-08-24 1987-08-24 Production of blood platelet growth factor

Publications (1)

Publication Number Publication Date
JPS6452792A true JPS6452792A (en) 1989-02-28

Family

ID=16581284

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62209946A Pending JPS6452792A (en) 1987-08-24 1987-08-24 Production of blood platelet growth factor

Country Status (1)

Country Link
JP (1) JPS6452792A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5325583A (en) * 1990-09-28 1994-07-05 Kabushiki Kaisha Toshiba Method for manufacturing printed circuit board

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5325583A (en) * 1990-09-28 1994-07-05 Kabushiki Kaisha Toshiba Method for manufacturing printed circuit board

Similar Documents

Publication Publication Date Title
EP0267155A3 (en) Bicyclic compounds
IT8547834A0 (en) PROCEDURE FOR TREATMENT OF CELLS WITH SOLUBLE BONE PROTEINS TO MAKE THEM SUITABLE FOR STIMULating THE GROWTH OF CARTILAGINE AND BONE TISSUES, AND THE PRODUCT OBTAINED
ATE76752T1 (en) BLOOD SUBSTITUTE.
ATE88097T1 (en) METHOD AND SYSTEM FOR REMOVAL OF IMMUNOSUPRESSIVE COMPONENTS FROM MAMMALIAN BLOOD.
IL126366A0 (en) Photopheresis treatment of leukocytes
LV11783A (en) Compounds and methods for stimulation of megakaryocyte growth and differentiation
FI881061A0 (en) A COMPOSITION WITH A FRIGOEROUS FOER PARENTERALT BRUK OCH DERAS ANVAENDNING.
GEP20002145B (en) Stem Cell Factor
ATE165010T1 (en) HUMAN IFN-BETA2/IL-6, ITS PURIFICATION AND USES
DE3268915D1 (en) Angiotropins of leukocytes and inflamed tissue: a new class of natural chemotropic protein mitogens for specific induction of directional growth of blood vessels, neovascularization of tissues and morphogenesis of blood vessel patterns, process for their biotechnical preparation and pharmaceutical compositions
HUT38654A (en) Process for producing cristalline calciumpseudomonate
PT77898A (en) Process for the preparation of substituted 4-amino-methylenochromanes and 4-aminomethylenecromenes acting on the blood circulation and application thereof in the preparation of pharmaceutical compositions acting on the blood circulation
EP0376251A3 (en) An anticoagulant substance obtained from urine
FI103577B1 (en) Method, DNA and microorganism for producing thrombolytic substance
JPS6452792A (en) Production of blood platelet growth factor
HU9401185D0 (en) Method and composition for determining the immunological activity of bioactive substances
FR2657783B1 (en) PROCESS FOR THE PREPARATION OF BLOOD DERIVATIVES AND DERIVATIVES OBTAINED BY THIS PROCESS.
ATE126437T1 (en) USE OF DEPOGEN TO TREAT RESTRICTED BLOOD CIRCULATION.
ZA873928B (en) Topical methotrexate preparation for the treatment of hyperproliferative epithelial disease
ES548007A0 (en) PROCEDURE FOR PREPARING DERIVATIVES OF 4-OXO-PIRIDO (2,3-D) PIRIMIDINA
SU1175457A1 (en) Method of recovery of bone stump
ES2004734A6 (en) Process for preparing conjugates of metalloproteins and derivatives thereof
FR2652744B1 (en) HEALING AND TISSUE REGENERATING COMPOSITION AND PROCESS FOR PREPARING THE SAME.
CA1266855C (en) Adsorbent and process for preparing the same
HUT47032A (en) Process for production of medical compositions dissolving blood cut